Literature DB >> 35943554

Long-term results of radio(chemo)therapy in metastatic carcinoma to cervical lymph nodes from an unknown primary. Adult Comorbidity Evaluation 27 score as a predictor of survival.

Miloslav Pala1, Pavla Novakova2, Zdena Pechacova3, Lucie Vesela3, Antonin Vrana3, Jarmila Sukova3, Petra Holeckova3, Tereza Drbohlavova3, Tomas Podlesak4, Lubos Petruzelka3,5.   

Abstract

PURPOSE: To evaluate the effectiveness and toxicity of curative (chemo)radiotherapy in patients with metastatic carcinoma to cervical lymph nodes from an unknown primary.
METHODS: Retrospective study of 90 consecutive patients, treated with curative radiotherapy from 2003 to 2018 (median age 59 years; current/former smokers 76%) was conducted. The distribution of nodal staging was as follows: N1: 12%, N2a: 21%, N2b: 43%, N2c: 10%, N3: 13%. In 62% of patients, neck dissection was performed before radiotherapy. Concomitant chemotherapy was given to 64% of patients.
RESULTS: The median follow-up of surviving patients was 86 months. The median total radiotherapy dose achieved was 70 Gy. The 5‑ and 10-year locoregional control were 84% in both cases, while 5‑ and 10-year distant control were 90% and 89%, respectively. A primary tumor in the head and neck area was detected in only 2 patients. No patient had an initial failure in the pharyngeal axis or contralateral cervical nodes. The 5‑ and 10-year overall survival were 55% and 42%, respectively. Severe early toxicity occurred in 71%; severe late toxicity in 33% of patients. Multivariate analysis demonstrated N‑status (hazard ratio [HR] 2.424; 95% confidence interval [CI] 1.121-5.241; p = 0.024) and comorbidity scores assessed by ACE-27 (Adult Comorbidity Evaluation; HR 3.058; 95% CI 1.489-6.281; p = 0.002) as two independent prognostic factors for overall survival.
CONCLUSION: The results of our work study demonstrate the high effectiveness of curative (chemo)radiotherapy on the pharyngeal axis and bilateral cervical nodes with long-term locoregional and distant control in 3/4 of the treated patients. N‑status and comorbidity scores were shown as strong prognostic factors influencing overall survival.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  ACE-27; Carcinoma of unknown primary; Chemoradiotherapy; Curative radiotherapy; Prognostic Factors

Year:  2022        PMID: 35943554     DOI: 10.1007/s00066-022-01983-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   4.033


  59 in total

1.  Cervical metastasis from occult carcinoma.

Authors:  M S COMESS; O H BEAHRS; M B DOCKERTY
Journal:  Surg Gynecol Obstet       Date:  1957-05

2.  Head and neck squamous cell carcinoma from an unknown primary site.

Authors:  Audrey Wallace; Greg M Richards; Paul M Harari; Jessica M Kirwan; Christopher G Morris; Haritha Katakam; William M Mendenhall
Journal:  Am J Otolaryngol       Date:  2010-08-17       Impact factor: 1.808

3.  Squamous cell carcinomas metastatic to cervical lymph nodes from an unknown head-and-neck mucosal site treated with radiation therapy alone or in combination with neck dissection.

Authors:  H S Erkal; W M Mendenhall; R J Amdur; D B Villaret; S P Stringer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-05-01       Impact factor: 7.038

4.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

Authors:  J D Cox; J Stetz; T F Pajak
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

5.  Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology.

Authors:  C Grau; L V Johansen; J Jakobsen; P Geertsen; E Andersen; B B Jensen
Journal:  Radiother Oncol       Date:  2000-05       Impact factor: 6.280

Review 6.  Cancer of unknown primary site.

Authors:  Nicholas Pavlidis; George Pentheroudakis
Journal:  Lancet       Date:  2012-03-12       Impact factor: 79.321

7.  [Therapy pf cervical lymph node metastases of unknown primary tumor].

Authors:  M J Kirschner; R Fietkau; F Waldfahrer; H Iro; R Sauer
Journal:  Strahlenther Onkol       Date:  1997-07       Impact factor: 3.621

Review 8.  Occult primary head and neck carcinoma.

Authors:  Cecelia E Schmalbach; Frank R Miller
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

9.  Diagnostic strategies in cervical carcinoma of an unknown primary (CUP).

Authors:  Inge Haas; Thomas K Hoffmann; Rainer Engers; Uwe Ganzer
Journal:  Eur Arch Otorhinolaryngol       Date:  2002-05-01       Impact factor: 2.503

Review 10.  Cervical lymph node metastases of squamous cell carcinoma from an unknown primary.

Authors:  Barbara A Jereczek-Fossa; Jacek Jassem; Roberto Orecchia
Journal:  Cancer Treat Rev       Date:  2004-04       Impact factor: 12.111

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.